ECTRIMS 2020 – www.brainwork.md

18th September 2020

Ageing in multiple sclerosis – what do we know?

https://www.brainwork.md/content/uploads/2020/09/Brainwork-Ageing-in-multiple-sclerosis-–-what-do-we-know.png 2846 1601 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 18th September 2020 23rd September 2020

“Ageing comes with many issues in multiple sclerosis (MS): progression, comorbidities, cognition problems and response to treatment”, Pierre Duquette (Department of Neuroscience, University of Montreal, Canada), the chair of the…

Anna Stelling, PhD
0
0

18th September 2020

How to promote remyelination in MS

https://www.brainwork.md/content/uploads/2020/09/Brainwork-How-to-promote-remyelination-in-MS.png 2846 1601 Anne Carter, MA (Cantab) Anne Carter, MA (Cantab) https://secure.gravatar.com/avatar/8a0679fc29066255ffcb2a69eacf9ee3?s=96&d=mm&r=g 18th September 2020 18th September 2020

Strategies to promote remyelination was a hot topic at this year’s virtual ACTRIMS/ECTRIMS joint meeting, with three expert presenters each addressing a different aspect of the subject, including the role…

Anne Carter, MA (Cantab)
0
0

17th September 2020

Does the microbiome have a role in MS?

https://www.brainwork.md/content/uploads/2020/09/MPR761-KSA-Content-Development-Brainwork-ECTRIMS-20200918_bacteria-article-2.png 2846 1600 Anne Carter, MA (Cantab) Anne Carter, MA (Cantab) https://secure.gravatar.com/avatar/8a0679fc29066255ffcb2a69eacf9ee3?s=96&d=mm&r=g 17th September 2020 18th September 2020

Can the bacteria living in your gut influence multiple sclerosis (MS) susceptibility and risk of relapse? That was the question Emmanuelle Waubant (University of California, San Francisco, USA) posed during…

Anne Carter, MA (Cantab)
0
0

17th September 2020

Is disease-modifying treatment in primary progressive multiple sclerosis effective after all?

https://www.brainwork.md/content/uploads/2020/09/Brainwork-ECTRIMS-Is-disease-modifying-treatment-primary-progressive-multiplesclerosis-effective-after-all-scaled.jpg 1703 2560 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 17th September 2020 18th September 2020

Until now, several randomised controlled trials and real-world studies could not show the clinical benefit of disease‑modifying treatments (DMTs) in primary progressive multiple sclerosis (PPMS).1-4 However, some recently published results…

Anna Stelling, PhD
0
0

17th September 2020

Neurofilament light chain levels as a biomarker in multiple sclerosis

https://www.brainwork.md/content/uploads/2020/09/Brainwork-ECTRIMS-Neurofilament-light-chain-levels-as-a-biomarker-in-multiple-sclerosis-scaled.jpg 1703 2560 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 17th September 2020 18th September 2020

It has been previously shown that the neuronal cytoskeletal protein neurofilament light chain (NfL) is released into the blood and cerebrospinal fluid (CSF) upon neuroaxonal injury.1 Hence it was not…

Anna Stelling, PhD
0
0

17th September 2020

Do hormonal changes influence MS in women?

https://www.brainwork.md/content/uploads/2020/09/Brainwork-Do-hormonal-changes-influence-MS-in-women.jpg 2400 1600 Anne Carter, MA (Cantab) Anne Carter, MA (Cantab) https://secure.gravatar.com/avatar/8a0679fc29066255ffcb2a69eacf9ee3?s=96&d=mm&r=g 17th September 2020 23rd September 2020

There is a paradox in multiple sclerosis (MS): females appear to be more susceptible to the disease than males, but also have a better long-term prognosis. Could this be due…

Anne Carter, MA (Cantab)
0
0